Stabilized pre-fusion rsv f proteins
AssigneeJanssen Vaccines & Prevention B.V.
InventorJohannes Petrus Maria LANGEDIJK
Life of this patent
Estimating the term…
Abstract
The present invention provides stable pre-fusion respiratory syncytial virus (RSV) F proteins, immunogenic compositions comprising said proteins and uses thereof for the prevention and/or treatment of RSV infection.
Claims22
A recombinant pre-fusion respiratory syncytial virus (RSV) Fusion (F) protein comprising one or more stabilizing amino acids, wherein the one or more stabilizing amino acids are present on position 79, 101, 152, 226, 354 and/or 486.
-9. (canceled)
-15. (canceled)
A method of inducing an immune response against respiratory syncytial virus (RSV) Fusion (F) protein in a subject, comprising administering to the subject a recombinant pre-fusion RSV F protein comprising stabilizing amino acids, wherein the stabilizing amino acids are present on one or more of positions 79, 101, 152, 226, 354 and/or position 486.
A method of preventing and/or treating a respiratory syncytial virus (RSV) infection in a subject in need thereof, comprising administering to the subject a recombinant pre-fusion RSV F protein comprising stabilizing amino acids, wherein the stabilizing amino acids are present on one or more of positions 79, 101, 152, 226, 354 and/or position 486.
Dependencies are inferred from the claim text.